First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study

OEGSTGEEST, Netherlands, Aug. 31, 2023. ISA Pharmaceuticals B.V., a clinical-stage biotech company developing immunotherapies to treat cancers and serious infectious diseases, is pleased to announce that the first patient has been dosed in the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials